Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of paeoniflorin

A technology of paeoniflorin and drugs, applied in the field of medicine, can solve the problems of long course of treatment, high cost, and ineffective effects

Inactive Publication Date: 2018-06-15
KUNMING UNIV OF SCI & TECH
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the clinical treatment of allergic diseases mainly adopts symptomatic treatment, such as the use of antihistamine drugs and hormones, and allergen-specific immunotherapy (Allergen-specific immunotherapy). Long time, high cost, and sometimes the effect is not obvious

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of paeoniflorin
  • New application of paeoniflorin
  • New application of paeoniflorin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Experimental purpose and method: No matter what kind of drug, if the concentration is too high, it will have cytotoxic effect on the cells. Too high concentration of paeoniflorin will cause certain toxicity to P815 cells. In order to detect the toxicity of paeoniflorin to P815, CCK- 8 Experiments were performed to test the cell survival rate of different concentrations of paeoniflorin after stimulating P815 for 24 hours to determine the concentration of paeoniflorin that has no growth inhibitory activity on the cells. The specific steps are as follows:

[0020] (1) Cultivation and passage of mast cell line P815

[0021] A. Cultivation of P815 cells: P815 was cultured in high glucose DMEM medium, containing 10% fetal bovine serum (FBS), 1% penicillin, cultured at 37°C, 5% CO 2 Environment;

[0022] B. Passaging of P815 cells: When the cell density in step A reaches 70%, passaging is required. Collect the cell culture fluid in the culture flask in a centrifuge tube, rinse three ...

Embodiment 2

[0030] Experimental purpose and method: In order to verify whether paeoniflorin can inhibit mast cell degranulation, mast cells were pretreated with different concentrations of paeoniflorin to detect whether it can inhibit the release of mast cell degranulation marker β-hexosaminidase. Specific steps as follows:

[0031] (1) Cultivation and passage of mast cell line P815

[0032] A. Cultivation of P815 cells: P815 was cultured in high glucose DMEM medium, containing 10% fetal bovine serum (FBS), 1% penicillin, cultured at 37°C, 5% CO 2 Environment;

[0033] B. Passaging of P815 cells: When the cell density in step A reaches 80%, passaging is required. Collect the cell culture fluid in the culture flask in a centrifuge tube, rinse three times with preheated phosphate buffered saline solution, and add appropriate amount of trypsin. After the cells are completely digested, add the cell culture medium to neutralize the trypsin, pipette evenly, centrifuge at 800 rpm for 3 minutes, remove...

Embodiment 3

[0041] Experimental purpose and method: To detect the effect of paeoniflorin on the expression of IL-4, IL-6, IL-12, IL-13, PAR2, PAR3, PAR4 at the mRNA level after P815 activation, the specific steps are as follows:

[0042] (1) Cultivation and passage of mast cell line P815

[0043] A. Cultivation of P815 cells: P815 was cultured in high glucose DMEM medium, containing 10% fetal bovine serum, 1% penicillin, and cultured at 37°C, 5% CO 2 Environment;

[0044] B. Passaging of P815 cells: When the cell density in step A reaches 70%, passaging is required. Collect the cell culture fluid in the culture flask in a centrifuge tube, rinse three times with preheated phosphate buffered saline solution, and add appropriate amount of trypsin. After the cells are completely digested, add the cell culture medium to neutralize the trypsin, pipette evenly, centrifuge at 800 rpm for 3 minutes, remove the supernatant, add fresh high-sugar DMEM medium and pipette to mix the cells, and pass the cells ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses new application of paeoniflorin, particularly relates to application of the paeoniflorin to preparation of a medicine for treating I type hypersensitivity reaction caused by hypertrophy cell activation, and belongs to the field of medicine. Through construction of a C48 / 80 induced P815 hypertrophy cell extracellular inflammation model, the invention discovers that the paeoniflorin has the effect of inhibiting hypertrophy cell activation, can effectively inhibit the degranular degree of the hypertrophy cells under the sensitization state and relieve release of beta-aminophenin, can inhibit expression of inflammatory genes IL-4, IL-6, IL-12 and IL-13 and expression of key receptors PAR2, PAR3 and PAR4 in a hypertrophy cell activation path on the mRNA level, and can obviously limit the phosphorylation level of ERK in an intracellular signal path.

Description

Technical field [0001] The invention belongs to the field of medicine, and specifically relates to the new use of paeoniflorin, and more specifically the application of paeoniflorin in the preparation of drugs for treating type I hypersensitivity caused by activation of mast cells. Background technique [0002] Allergic diseases (allergic diseases), including allergic rhinitis, asthma, conjunctivitis, eczema, food allergy, etc., are common and frequently-occurring diseases in clinical practice, and have been listed as the 21st world priority by the World Health Organization (WHO) One of the three major diseases to be prevented is a major global hygiene problem. [0003] According to statistics from the World Allergy Organization (WAO), the incidence of allergic diseases has increased by at least 4-5 times in the past 30 years, and is increasing at a rate of more than 1% per year. The current global prevalence has reached 22%. It is estimated that in 20 years, 50% of the population...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P37/08
CPCA61K31/7048
Inventor 安输虞姣姣徐天瑞张家静
Owner KUNMING UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com